Lihua Cao

机构：First Hospital of Qinhuangdao · ORCID：0000-0002-4664-9003

发表论文 21 篇 · 总被引 206 次 · h-index 9

代表论文

• Efficacy and safety of tenofovir alafenamide fumarate for preventing mother‐to‐child transmission of hepatitis B virus: a national cohort study (2020 · Alimentary Pharmacology & Therapeutics · 被引 48)
• Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients (2019 · World Journal of Gastroenterology · 被引 28)
• Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease (2022 · Frontiers in Physiology · 被引 22)
• An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir (2022 · Journal of Clinical and Translational Hepatology · 被引 17)
• [Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection]. (2019 · PubMed · 被引 14)
• Liver Stiffness Measurement Can Reflect the Active Liver Necroinflammation in Population with Chronic Liver Disease: A Real-world Evidence Study (2019 · Journal of Clinical and Translational Hepatology · 被引 13)